Maegim한국어

위더스제약

330350KOSDAQSector: Pharma & Biotech
₩6,280▲ 0.48%Market cap ₩82.9BAs of Jul 21, 2026 close · updated once daily
A
Grade A65.4 ptsTop 20% of 2,523 stocks
Financial strength
65.2
Growth momentum
56.6
Price attractiveness
71.8

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

65.2
How much debt does it carry relative to equity?
Debt-to-equity ratio
39.4%
✓ Above median · Top 37.6% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
206.2%
✓ Above median · Top 45.7% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
5.3%
✓ Above median · Top 28.2% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
5.1%
✓ Above median · Top 27.8% in sector
Sector median -4.5%

Source filing: annual report (separate) — view original ↗

2

Growth momentum

56.6
How much did revenue grow in a year?
Revenue growth (YoY)
3.6%
✗ Below median · Top 59.1% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
18.1%
✓ Above median · Top 14.6% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
0.0%
✗ Below median · Top 55.1% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
16.1%
✓ Above median · Top 44.9% in sector
Sector median 3.5%

Source filing: annual report (separate) — view original ↗

3

Price attractiveness

71.8
Is the price expensive relative to earnings?
P/E (price-to-earnings)
16.7x
✓ Above median · Top 23% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.85x
✓ Above median · Top 33.5% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15